Cancer Research
Metformin Blocks Cancer-Causing Blood Cell Mutations in 400K+ People
Large UK study reveals metformin users have dramatically lower rates of dangerous DNMT3A mutations that lead to blood cancer.
Research Paper
Apr 13, 2026 0
Results for "Metformin TAME Trial" in Cancer
20 articles
Cancer Research
Metformin Shows Minimal Effect on Blood Cell Mutations Linked to Cancer Risk
Large study finds diabetes drug metformin only slightly slows harmful blood cell mutations, questioning its use for cancer prevention.
Research Paper
Mar 29, 2026 1
Cancer Research
New c-Met Antibody-Drug Conjugate Shows Promise in Late-Stage Colorectal Cancer
Phase I trial of Temab-A reports 15.6% response rate and 74.6% disease control in heavily pretreated metastatic colorectal cancer patients.
Research Paper
May 3, 2026 0
Cancer Research
Talquetamab Shows 60% Response Rate in Japanese Myeloma Patients with No Dose-Limiting Toxicity
Phase 1 data from 15 heavily pretreated Japanese myeloma patients confirms talquetamab's safety and efficacy, matching global trial results.
Research Paper
Jun 15, 2026 0
Cancer Research
Targeted Therapy Shows Promise for Aggressive Brain Cancer in Precision Medicine Trial
Phase 1/2 umbrella trial matches glioblastoma patients to targeted treatments based on tumor genetics, with temsirolimus showing significant benefit.
Research Paper
Apr 4, 2026 0
Cancer Research
Tumor-Targeted CD40 Antibody Shows Safe Profile but Limited Tumor Shrinkage in Phase 1 Trial
RO7300490, a FAP-targeted CD40 agonist, proved manageable in 80 advanced cancer patients but produced no objective tumor responses despite clear immune activation.
Research Paper
May 2, 2026 0
Cancer Research
Novel Tumor-Targeted CD40 Drug Safely Reprograms Cancer Immune Environment
Phase 1 trial shows MP0317 activates anti-tumor immunity in solid tumors with a favorable safety profile, supporting combination therapy.
Research Paper
May 2, 2026 0
Cancer Research
GLP-1 Drugs Like Ozempic Show Unexpected Cancer Protection Benefits
New research reveals popular weight-loss medications may reduce cancer risk beyond their metabolic benefits.
Research Paper
Mar 29, 2026 1
Cancer Research
Immunotherapy Plus T-DXd Shows Strong Results in HER2-Low Breast Cancer
The BEGONIA trial finds durvalumab combined with trastuzumab deruxtecan achieves 62% response rate in hard-to-treat metastatic breast cancer.
Research Paper
Jun 9, 2026 0
Cancer Research
Vitamin D Receptor Agonist Reshapes Pancreatic Cancer's Defensive Shield
A phase trial finds paricalcitol safely remodels the tumor microenvironment in metastatic pancreatic cancer, boosting immune cell infiltration.
Research Paper
May 26, 2026 0
Cancer Research
Radiation to Metastases Cuts Cancer Progression Risk in Half in Phase II Trial
Adding targeted radiation to standard therapy reduced progression by 46% across multiple cancer types in the EXTEND trial.
Research Paper
May 19, 2026 0
Cancer Research
New Triple Drug Combo Doubles Survival for Brain Metastases in HER2+ Breast Cancer
Tucatinib-based treatment extends survival from 4.4 to 10 months for women with breast cancer that spread to brain lining.
Research Paper
Mar 28, 2026 0
Cancer Research
Chemotherapy Plus Hormones vs Hormones Alone for Older Women with High-Risk Breast Cancer
ASTER 70s trial compares treatment intensities for women 70+ with genomically high-risk breast cancer to optimize outcomes while minimizing toxicity.
Research Paper
Apr 4, 2026 0
Cancer Research
DCA Metabolic Conditioning Creates Superior Cancer-Fighting T Cells
Redirecting glucose metabolism during T cell expansion dramatically improves cancer immunotherapy effectiveness.
Research Paper
Mar 29, 2026 0
Cancer Research
Multi-Drug Cancer Strategy Blocks Key Growth Pathway Better Than Single Drugs
Combining two targeted drugs plus dietary changes shows superior cancer-fighting potential in lab studies of breast and endometrial cancers.
Research Paper
Apr 2, 2026 0
Cancer Research
Cancer Drug Combo Shows Promise for Aggressive Endometrial Cancer Subtype
New combination therapy achieved 32% response rate in hard-to-treat endometrial cancer patients with specific genetic markers.
Research Paper
Mar 28, 2026 0
Cancer Research
Gene Therapy Delivers Immune Signals Directly Into Brain Tumors in First Human Trial
A phase 1 trial shows Temferon โ a gene-engineered stem cell therapy โ safely delivers interferon-ฮฑ into glioblastoma tumors with no dose-limiting toxicities.
Research Paper
Jun 2, 2026 0
Cancer Research
New Drug Combo Shows 55% Response Rate Against Aggressive Lung Cancer Subtype
Tislelizumab plus anlotinib achieved promising results in treating advanced pulmonary sarcomatoid carcinoma with manageable side effects.
Research Paper
Mar 28, 2026 0
Cancer Research
Daratumumab Shows Promise for High-Risk Smoldering Multiple Myeloma
New NEJM study compares early treatment with daratumumab versus watchful waiting for high-risk smoldering multiple myeloma patients.
Research Paper
Apr 9, 2026 0
Cancer Research
FGFR Inhibitor Achieves 42% Response Rate in Rare SDH-Deficient Stomach Tumors
A phase 2 trial shows rogaratinib produces durable responses in a hard-to-treat GIST subtype driven by epigenetic oncogene activation.
Research Paper
May 29, 2026 0
Page 1 of 2Next